Evogene
EVGN
33 hedge funds and large institutions have $3.85M invested in Evogene in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 4 closing their positions.
41% more capital invested
Capital invested by funds: $2.73M → $3.85M (+$1.11M)
0.02% less ownership
Funds ownership: 0.93% → 0.91% (-0.02%)
6% less funds holding
Funds holding: 35 → 33 (-2)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $6K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$126K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$62.9K |
| 3 |
JP Morgan Chase
New York
|
+$18.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$18.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$153K |
| 2 |
Walleye Capital
New York
|
-$105K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$17.6K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$8.62K |
| 5 |
HF
HRT Financial
New York
|
-$8K |
EVGN Hedge Fund Activity: Q4 2023 in Review
33 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2023, worth a combined $3.85M — up 41% from $2.73M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EVGN and 2 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Morgan Stanley, adding an estimated $126K. The largest seller was CVI Holdings, exiting entirely with an estimated $153K sold.
- 33 institutional investors held Evogene (EVGN) as of Q4 2023, down from 35 in Q3 2023.
- Funds reported $3.85M of Evogene stock for Q4 2023, up 41% quarter-over-quarter.
- 2 funds opened new Evogene positions in Q4 2023 and 4 closed out, a net change of -2 holders.
- The largest Evogene buyer in Q4 2023 was Morgan Stanley, an estimated $126K added.
- The largest Evogene seller in Q4 2023 was CVI Holdings, an estimated $153K sold.
Based on aggregated 13F filings for Q4 2023.